SuperworthProthena Corp Public EPS PRTA
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- −$0.84
- Latest quarter, Q2 FY26
- −$0.36
- Fiscal year 2025
- −$4.54
Prothena Corp Public's earnings per share was −$0.84 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.36.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.54 | n/a |
| FY2024 | −$2.30 | n/a |
| FY2023 | −$2.80 | n/a |
| FY2022 | −$2.50 | −329% |
| FY2021 | $1.09 | n/a |
| FY2020 | −$2.79 | n/a |
| FY2019 | −$1.95 | n/a |
| FY2018 | −$3.94 | n/a |
| FY2017 | −$4.06 | n/a |
| FY2016 | −$4.66 | n/a |
| FY2015 | −$2.63 | n/a |
| FY2014 | −$0.12 | n/a |
| FY2013 | −$2.22 | n/a |
| FY2012 | −$2.84 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.36 | n/a | −$0.84 | |
| Q1 FY26 | $0.60 | n/a | −$2.82 | |
| Q4 FY25 | −$0.40 | n/a | −$4.54 | |
| Q3 FY25 | −$0.68 | n/a | −$5.22 | |
| Q2 FY25 | −$2.34 | −292% | −$5.64 | |
| Q1 FY25 | −$1.12 | n/a | −$2.08 | |
| Q4 FY24 | −$1.08 | n/a | −$2.30 | |
| Q3 FY24 | −$1.10 | −389% | −$2.48 | |
| Q2 FY24 | $1.22 | n/a | −$1.00 | |
| Q1 FY24 | −$1.34 | n/a | −$3.25 | |
| Q4 FY23 | −$1.26 | −1069% | −$2.80 | |
| Q3 FY23 | $0.38 | n/a | −$1.41 |
Against its peers
Companies in Drug Manufacturers - General nearest Prothena Corp Public's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PRTAProthena Corp Public | −$0.84 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Prothena Corp Public
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.